Background and Objective Conflicting findings from studies evaluating the association between use of antidepressant drugs and mortality have been reported. We tested the hypothesis that better adherence to antidepressant therapy may reduce mortality. Methods The cohort included 29,845 individuals aged C 65 years from several Italian health units who were newly treated with antidepressant drugs after hospital discharge with a diagnosis for cardiovascular disease during 2008-2010. These individuals were observed from the first prescription until the end of data availability (i.e. 2012-2014, depending on the local database). During this period, information on (1) prescription of antidepressants and other medications and (2) death from any cause (outcome) was recorded. Proportional hazards models were fitted to estimate the association between better adherence to antidepressants (defined as proportion of days covered C 75%) and outcome, by adjusting and stratifying for several covariates.
Results Patients with better adherence to antidepressants had a reduced mortality of 9% (95% CI [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Patients who did not use other medicaments during follow-up had reduced mortality associated with better adherence to antidepressants of 21% (-1-38), 14% (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , 20% (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) and 13% (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) for no users of antihypertensive agents, lipid-lowering agents, other cardiovascular drugs and antidiabetics, respectively. Conclusions Better adherence to antidepressants is associated with reduced all-cause mortality, mainly in patients who did not use other pharmacological treatments. Behavioural changes to enhance adherence among the elderly with cardiovascular disease might offer important benefits in reducing their mortality.
Key Points
Better adherence to antidepressants may decrease all-cause mortality among elderly previously hospitalized by cardiovascular diseases.
Better adherence to antidepressants is associated with reduced mortality, mainly among elderly with cardiovascular diseases who did not use comedications.
The findings provided by this study may result in a considerable public health impact and may support both clinical practice and regulatory activities.
Introduction
Due to its high prevalence, depression is a serious public health concern. Currently, it is estimated to affect over 350 million people worldwide and up to a quarter of the European population [1] . One in five older people experience anxiety and/or depression, the prevalence of which continues to increase with age [2] . Prevalence of anxiety and depression is reported to be high among people with co-morbid long-term conditions [3] . Although prevalence of depression among patients with cardiovascular disease (CVD) varies according to the specific disease processes and assessment method [4] , around 50% of patients experience major or minor depression at least once in the course of CVDs [5] .
Adequate treatment of depression by means of antidepressant drugs (ADs) should be considered as a compelling public health intervention aimed to reduce the burden of avoidable morbidity, disability and mortality. Nevertheless, adherence and persistence to ADs, although measured differently, has been reported to be very low, with on average 20% of people who start drug therapy showing proper adherence [6] [7] [8] [9] , even among patients suffering from CVD [10] [11] [12] .
Studies addressing the relationship between the use of ADs and mortality among CV patients are conflicting. In fact, with respect to no users, those who used ADs are reported to be at increased [13] [14] [15] and decreased [16] mortality, even after correcting estimates for diagnosis of depressive disorders. Furthermore, although CV patients who properly adhered to ADs consistently showed reduced mortality compared with those treated insufficiently [10, 17, 18] , methodological shortcomings could have generated biased estimates. In particular, inclusion of prevalent users of ADs leads to the selective inclusion of those patients who maintained drug therapy [19] . In addition, the incomplete data on the clinical profile of the included patients, particularly CV co-medications, does not allow recognition of the effect of adherence to ADs compared with that of adherence to other drugs.
To address these gaps in our knowledge, we tested the hypothesis that better adherence to ADs may reduce the mortality among elderly patients (i.e. aged 65 years or older) with CVD. The study is a part of an Italian project funded by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA), which supported the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE) for assessing the appropriateness of outpatient drug prescriptions in the Italian elderly discharged from hospital for CVD.
Methods

Data Sources
In Italy, the National Health Service (NHS) provides universal and free-of-charge coverage for the so-called essential healthcare services. The program is administered by an automated system of healthcare utilization (HCU) databases that collect a variety of information, including at least (1) an archive of residents who receive NHS assistance (i.e. practically the entire resident population), including demographic data (e.g. age, gender), as well as the date on which the individual started (because he/she was born or immigrated) or stopped (because he/she was dead or emigrated) the beneficiary conditions of the Italian NHS; (2) a database on hospital discharge records including information on primary diagnosis and up to five coexisting conditions and procedures coded according to the International Classification of Diseases, Clinical Modification 9th revision (ICD-9 CM); (3) a drug prescription database providing information on outpatient drug prescriptions reimbursed by the NHS and coded according to the Anatomical Therapeutic Chemical (ATC) classification system (i.e. the drug classification recommended by the World Health Organization [20] ).
Setting
Data used for the present study were retrieved from the HCU databases from five Italian territorial units participating in the I-GrADE project, namely three regions (Lazio, Lombardy and Tuscany) and two local Health Units (Caserta and Treviso). Data from about 21 million beneficiaries residing in these areas (accounting for nearly 35% of the Italian population) were recorded in the corresponding databases.
To obtain the complete history of healthcare utilization of NHS beneficiaries from these territorial units, the different pieces of information collected by the above mentioned HCU databases need to be linked by using a unique personal identification code. In order to preserve privacy, the original identification code was replaced with its digest, i.e. the image of the code through a cryptographic hash function. Data were extracted and processed locally by using a common Statistical Analysis System (SAS) program according to the study protocol.
The ICD-9 CM and ATC codes used in the present study are respectively reported in Supplementary Tables S1 and S2.
Cohort Selection and Follow-up
NHS beneficiaries were eligible for entry into the study cohort if during 2008-2010 they: (1) were residents in the participating healthcare territorial units; (2) were aged 65 years or older; (3) were hospitalized at least once for selected CVD (heart failure, cerebrovascular disease, ischaemic heart disease or arrhythmia); (4) were discharged alive from the first occurring CV hospital admission (i.e. the index hospitalization); (5) received at least one prescription of ADs within 1 year after the index hospitalization. Antidepressants included selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs) and newer atypical antidepressants (NAAs).
Eligible patients were excluded if they (1) received an antidepressant drug within at least 3 years before cohort entry, so as to reduce the potential for the selective inclusion of patients with longer treatment survival (i.e. a new-user design was adopted for the current study [19] ), (2) did not receive ADs within 1 year after discharge from the index hospitalization, so as to reduce the potential for confounding by indication (i.e. the user-only paradigm was followed in our study [21] ); (3) were hospitalized for cancer or received antineoplastic and immunomodulating drug therapy, so as to exclude patients who had high mortality at baseline; (4) had less than 3 years of look-back prior to the cohort entry or less than 6 months of follow-up, to ensure enough time for observation, respectively, backwards, for baseline covariates measurement, and forwards, for exposure assessment.
The remaining patients were included in the study cohort and accumulated person-years of follow-up starting from the cohort entry (i.e. the first prescription of AD occurred within a year after the discharge date for the index hospitalization) until the occurrence of death for any cause (study outcome), emigration or the end of the study period.
As there were differences in data availability across databases of the participating healthcare territorial units, the study period ended at 31 December 2011 for Lazio, 31 December 2012 for Lombardy, Tuscany and Caserta, and 31 December 2014 for Treviso.
Because we had no information about drug prescriptions for inpatients, with the aim of assessing the potential impact of the so-called immeasurable time bias, i.e. the differential misclassification due to unmeasured drug exposure during hospitalizations [22] , we did not account for the follow-up time corresponding to any hospitalization event plus 10 days after hospital discharge.
Outcome Ascertainment
We identified deaths from the archive of residents, who receive NHS assistance, in which the date of possible death for all citizens, who were NHS beneficiaries during the study period, is recorded. At the time the current study was carried out, the cause of death was not recorded in that source for most of the participant territorial units.
Adherence to Antidepressants
We identified all prescriptions of ADs dispensed to the cohort members during follow-up. The duration of each prescription was calculated by dividing the total amount of the drug prescribed by the defined daily dose (DDD), i.e. the ''assumed average maintenance dose per day for a drug used for its main indication in adults'' [20, 23] . For overlapping prescriptions, the cohort member was assumed to have completed the first prescription before starting the second. Starting from the cohort entry, consecutively refilled prescriptions were considered uninterrupted if the time-span between the end of one prescription and the beginning of the following one (or of censoring) was 30 days or shorter. Adherence to ADs was measured by the ratio between the cumulative number of days in which the medication was available (i.e. the duration in days of each uninterrupted sequence of refilled ADs) and the days of the overall follow-up (proportion of days covered, PDC) [24] . Cohort members were classified as poorly (PDC \ 75%) or highly (C 75%) adherent accordingly [25] . Supplementary  Fig. S1 shows adherence to ADs measured in the current paper.
Covariates
Cohort members were assessed for several covariates. Among these, baseline characteristics included age, gender, class of AD first prescribed (i.e. SSRIs, TCAs, NAAs or a combination of at least two ADs), main diagnosis at index hospitalization (heart failure, cerebrovascular disease, ischaemic heart disease or arrhythmia), co-morbidities and co-medications. The Charlson comorbidity score [26] , based on 17 conditions weighted according to their prognostic importance, was calculated for conditions identified from inpatient charts recorded within the 3 years prior the cohort entry, and categorized as 0, 1 or C 2. Co-medications dispensed in the year prior to cohort entry were chosen according to their wide use and prognostic relevance. These included antiarrhythmic, antithrombotic, antihypertensive, lipid-modifying, other CV and antidiabetic agents, drugs for obstructive airway diseases and thyroid therapy, and antiepileptic, antiparkinsonian, psycholeptic and psychoanaleptic (excluding ADs) drugs. Oneyear prior cohort entry should be sufficient for capturing users of chronic medications such as those of interest to us. In addition, a polypharmacy score was calculated by counting the highest number of drugs with different 5-digit ATC codes dispensed in a day and categorized as 0, 1-4, 5-9 and C 10 prescriptions [27] .
Finally, the use of antihypertensive, lipid-modifying or other CV agents and antidiabetics was recorded during follow-up. Adherence to each of these medications was calculated among users with the same criteria described above for ADs.
Data Analysis
Individual-level data from all databases of participant territorial units were first gathered into a pooled dataset.
Chi-square, its version for the trend, and the t-test were used to test differences between poorly and highly adherent cohort members.
The Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and its 95% confidence interval (CI), for the effect of ADs as a whole, as well as each class of ADs, on the mortality. Adjustments were made for the above-listed covariates measured at baseline and during follow-up. The joint action of ADs and other drugs was assessed through the use of dummy variables that were obtained through the combination of AD adherence with three categories for each co-medication (no users and two levels of adherence). Since drug use and adherence may change over time, the assessment of its effect requires consideration of its cumulative and varying nature. This was done by including time-dependent covariates into the Cox model. Models were separately fitted according to strata of CV diagnosis at index hospitalization.
Sensitivity Analyses
With the aim of checking robustness of our estimates with respect to the adopted criteria for measuring adherence to ADs, two sensitivity analyses were performed. Firstly, other than a 30-time-span allowed for assigning two consecutive prescriptions to a unique uninterrupted sequence of refilled ADs, alternative lengths of 20 and 40 days were adopted. Secondly, other than the 75% PDC value for defining trade-off between poorly and highly adherent patients, more permissive (70%) and restrictive (80%) trade-offs were applied.
All analyses were performed using SAS software (version 9.2; SAS Institute, Cary, NC, USA). Statistical significance was set at the 0.05 level. All p-values were twosided.
Results
Patients
The process of selection of the study cohort is given in Fig. 1 . The 29,845 patients included in the final cohort accumulated 79,260 person-years (PYs) (on average 2.7 years per patient) and generated 7882 deaths, with a mortality rate of 99.4 for every 1,000 PYs. Among the 21,963 patients who survived, 7,973 were lost because of emigration, and the rest were followed until the end of the study period.
Among the 29,845 cohort members, only 5,959 (20%) adhered to ADs during follow-up. Table 1 shows that at baseline, compared to the highly adherent patients, patients who adhered poorly to ADs were older, were initially treated on monotherapy with SSRIs or NAAs, showed a slightly better clinical profile, and received more co-treatments. Conversely, during follow-up, with respect to individuals who adhered highly to ADs, those with poor adherence also had poor adherence to co-medications (except for CV drugs).
Adherence to Antidepressant Drug Therapy
and Mortality Figure 2 shows that, compared to the poorly adherent patients, highly adherent patients had reduced mortality of 16% (95% CI 11-21) and 9% (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) according to partially and fully adjusted estimates, respectively. There was statistical evidence that AD adherence was associated with reduced mortality among cohort members who had a main diagnosis of cerebrovascular disease at index hospitalization. The effect of adherence to ADs among patients affected by ischaemic heart disease, arrhythmia and heart failure, although directionally similar, was weaker and did not reach statistical significance. There was no statistical evidence of a difference in the effect of adherence to SSRIs and NAAs on mortality, the latter being respectively reduced by 10% (4-16) and 19% (7-30) (p = 0.188). As only 1,323 patients (4.4% of the entire cohort) started on TCAs, their effect was not investigated. Figure 3 shows that adherence to ADs increased survival in all categories of co-medication use. However, the protective action of high adherence to ADs was more pronounced among patients who did not use co-medications, or used them with poor adherence, than among users with high adherence to co-medications. In fact, compared to patients with poor AD adherence, those on high adherence had a reduced mortality of 21%, 9% and 8%, 14%, 13% and 1%, 20%, 15% and 7%, and 13%, 0.30% and 6%, respectively, among no users, poorly adherent and highly adherent users of antihypertensive medicaments, lipidlowering agents, other CV drugs and antidiabetics.
Sensitivity Analyses
Our main findings did not substantially change by varying criteria for calculating adherence to ADs. In fact, mortality was reduced to 19% (14-24) and 15% (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) by allowing 20 and 40 days for considering two consecutive prescriptions as belonging to the same uninterrupted sequence of refilled ADs. In addition, mortality was reduced to 14% (9-19) and 21% (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) by considering as highly adherent those patients who had a PDC C 70% and a PDC C 80%.
Discussion
Our study based on 'real-world' data of almost 30,000 elderly people who started AD treatment after hospital discharge for CV outcome provides further evidence that by enhancing adherence to ADs a substantial improvement in survival is expected. In particular, we observed that Adherence was assessed as the cumulative number of days during which medication was available divided by the number of days of follow-up, a quantity referred to as 'proportion of days covered' (PDC). Cohort members were classified according to whether PDC was \ 75% or C 75%, denoting them as poorly and highly adherent patients, respectively b According to t test (age), chi-square (gender, diagnosis at index hospitalization and co-medications during follow-up) or its version for the trend (categories of polypharmacy and Charlson comorbidity scores). Co-medication use and no use during follow-up, as well as PDC \ 75% and C 75% among co-medication users, were separately tested Adherence to therapy with antidepressants was assessed as the cumulative number of days during which the medication was available divided by the number of days of follow-up, a quantity referred to as 'proportion of days covered' (PDC). Cohort members were classified according to whether PDC was \ 75% or C 75%, denoting them as poorly and highly adherent patients, respectively. Hazard ratios, and 95% confidence, estimated with Cox proportional hazard models are shown. Estimates were partially adjusted (only for baseline covariates, i.e. gender, age, diagnosis at index hospitalization, class of antidepressant first employed, Charlson comorbidity score and polypharmacy score) and fully adjusted (also for comedication with selected CV drugs during follow-up) patients with better adherence had a significant reduction in mortality of 9%. In addition, our study showed that better adherence to ADs reduces mortality both in patients who did not use other selected co-medications or who poorly adhered to them. We observed that the beneficial effect of adherence to ADs was mainly exerted among patients who suffered from cerebrovascular disease. Finally, there was no evidence from our study that adherence to AD classes may differentially affect survival. In summary, our large population-based study supports the notion that continuous use of ADs is associated with a non-marginal increase in survival of the elderly with CVD. Investigations addressing the relationship between the use of ADs and mortality in CV patients report conflicting results, mainly because of differences in the design of the studies. At least four issues need to be discussed to fully appreciate and understand our findings. First, it is very difficult to understand whether the investigated association is the result of drug (ADs) or disease (depression) exposure by comparing patients who used and who did not use ADs [13] [14] [15] [16] 28] , unless information is available on the clinical diagnosis of depression [13] [14] [15] 28] , which it was not our case. Second, by including both current and new users of ADs (i.e. prevalent AD users [10, 13, 14, 17, 18] ), patients who did not continue AD drug therapy once it has begun are likely to be excluded, thus introducing biased estimates. As 'user-only' and 'new-user' designs demonstrated a reduction in the potential for confounding by indication and for the selection of surviving prevalent users [19, 21] , in our study participants were identified at the time of their initial AD drug therapy, and only users of ADs were included.
Third, the potential for confounding or effect modification exerted by co-medications, known to reduce mortality [29] , should be accounted for from studies investigating the relationship between ADs and mortality in CV patients. We observed that high adherence to ADs ensures greater survival among patients who did not Lipid modifying agents Fig. 3 Combined action of use of antidepressant and other selected drugs during follow-up on mortality. I-GrADE program, Italy, 2008-2014. PDC proportion of days covered. Adherence was assessed as the cumulative number of days during which medication was available divided by the number of days of follow-up, a quantity referred to as 'proportion of days covered' (PDC). Cohort members who used the considered drugs were classified according whether PDC was \ 75% or C 75%, denoting them as poorly and highly adherent patients, respectively. Hazard ratios, and 95% confidence, estimated with Cox proportional hazard models are shown. Estimates were adjusted for baseline co-variates (i.e. gender, age, diagnosis at index hospitalization, class of antidepressant first employed, Charlson comorbidity score and polypharmacy score) receive, or who received for a short time, pharmacological treatment for lowering blood pressure, cholesterol or glycaemia, or for treating angina, heart failure, atrial fibrillation or other arrhythmias. In these patients, better adherence to ADs could be a marker of more mindful health-related behaviours that improve prognosis (e.g. physical activity, healthy diet and smoking cessation) [17, 30] . On the other hand, although to a lesser extent, even patients who received the considered co-medications took advantage of AD therapy, suggesting that the effect of adherence to ADs on survival cannot be solely due to the correlated adherence to other medicaments. Finally, previously findings on the effect of individual classes of ADs on the risk of mortality in CV patients were based on a comparison with non AD users [13, 14] , and could again generate uncertainty about causality of the estimates. We found that adherence to SSRIs or NAAs homogeneously reduced mortality in our study, thus suggesting that the observed association might be causally explained by the efficacy of these two classes of ADs in relieving the symptoms of depression [31] .
Our study has several key strengths. One, it was based on a large unselected population, which was made possible because in Italy universal healthcare assistance is provided to virtually all citizens. Two, the drug prescription database provided highly accurate data, because pharmacists are required to report prescriptions in detail in order to obtain reimbursement, and incorrect reports about dispensed drugs have legal consequences [32] . Finally, the robustness of our findings was confirmed by changing criteria for defining exposure to ADs.
However, our study has some limitations. First, information about the indication for AD treatment, the causes of stopping drug therapies and the causes of death (e.g. deaths due to CVD, suicide or other cause) were not available in our database. Two, adherence to ADs was derived from drug prescriptions, i.e. a widely used method to estimate adherence to treatment in large populations [33] , which requires, however, the assumption that the proportion of days covered by a prescription corresponds to the proportion of days of drug use [34] . Therefore, the actual association between use of ADs and mortality might be understated owing this source of exposure misclassification. On the other hand, exposure misclassification also occurs when, as in our study, the DDD metric is used for measuring the duration of drug coverage [35] . Three, the relatively short (2.7 years on average) duration of followup may not be long enough for assessing mortality as an outcome measure. Finally, given its observational nature, caution is required in making inferences about causality from our study. Possible differential distribution of unmeasured characteristics between the compared groups (e.g. smoking, obesity, physical inactivity, unhealthy diet) might have confounded the observed association. However, adherence to ADs may play a positive role on the views of self-care in health, which could be associated with a reduction of mortality. In general, adherence may influence the increase in survival, rather than the role of the AD itself.
Conclusions
The present study suggests that survival was higher among subjects who were highly adherent to ADs among elderly patients with cerebrovascular disease, and perhaps with other major CVD. Survival increased 15% among patients who suffered cerebrovascular disease, and up to 20% among patients who were not treated with cardiovascular drugs. In these patients, however, poor adherence to ADs could be a marker of unhealthy behaviours that may explain the excess of mortality. Further studies are needed to better clarify mechanisms underlying the association between depression, AD drug therapy and mortality in frail patients.
